IDO inhibitors

1. A compound of formula (II)

wherein:

 is phenyl optionally substituted with halo,

R 1 is COOH or tetrazol-5-yl;

R 2 and R 3 are independently H;

R 4 and R 5 are independently H or halo;

R 6 is H;

R 7 and R 8 are independently H, C 1 -C 6 alkyl optionally substituted with halogen, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, aryl, C 1 -C 6 alkoxyl optionally substituted with C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl optionally substituted with C 1 -C 6 alkyl, and aryl C 1 -C 6 alkyl,

provided that only one of R 7 and R 8 is H,

or R 7 and R 8 are taken together with the nitrogen to which they are attached to form

R 9 is

 or —COOR 12 ;

R 10 is aryl optionally substituted with C 1 -C 6 alkyl, CN, haloalkyl, or halogen, C 1 -C 6 alkyl, 5- to 7-membered monocyclic heteroaryl optionally substituted with C 1 -C 6 alkyl, halo and CN;

R 11 is H or OH;

R 12 is aryl optionally substituted with C 1 -C 6 alkyl, nitro, halogen, alkoxyl, aryloxyl or benzodioxolyl;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

2. The compound as defined in claim 1 wherein

is phenyl, and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

3. The compound as defined in claim 1 wherein:

R 1 is tetrazol-5-yl or COOH;

R 2 is H and

R 3 is H,

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

4. The compound as defined in claim 1 wherein:

R 7 and R 8 are independently optionally substituted C 1 -C 6 alkoxyl, or optionally substituted C 3 -C 8 cycloalkyl;

or R 7 and R 8 are taken together with the nitrogen to which they are attached to form

and

R 9 is

or —COOR 12 ;

R 11 is H; and

R 12 is naphthyl, nitroaryl, phenyl, C 1 -C 6 alkylphenyl, C 1 -C 6 alkoxyphenyl,

C 1 -C 6 alkoxy(halo)phenyl, halophenyl, or phenyl-C 1 -C 6 -alkoxyphenyl;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

5. A compound selected from the group consisting of 4′-(Diisobutylamino)-5-fluoro-3′-(2-p-tolylacetamido)biphenyl-2-carboxylic acid; N-(4-(Diisobutylamino)-2′-(1H-tetrazol-5-yl)biphenyl-3-yl)-2-p-tolylacetamide; N,N-(4-(Benzyl(isobutyl)amino)-2′-(1H-tetrazol-5-yl)biphenyl-3-yl)-2-(2-(trifluoromethyl)phenyl)acetamide; 4′-(diisobutylamino)-3′-(2-p-tolylacetamido)biphenyl-2-carboxylic acid; 4′-(cyclohexyl(isobutyl)amino)-3′-(2-(2-fluorophenyl)acetamido)biphenyl-2-carboxylic acid; 4′-(cyclohexyl(isobutyl)amino)-5-fluoro-3′-(2-(2-fluorophenyl)acetamido)biphenyl-2-carboxylic acid; and N-(4-(cyclohexyl(isobutyl)amino)-2′-(1H-tetrazol-5-yl)biphenyl-3-yl)-2-(2-(trifluoromethyl) phenyl)acetamide and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

6. The compound that is 4′-(Diisobutylamino)-5-fluoro-3′-(2-p -tolylacetamido)biphenyl-2-carboxylic acid; N-(4-(Diisobutylamino)-2′-(1H-tetrazol-5-yl)biphenyl-3-yl)-2-p -tolylacetamide or a pharmaceutically acceptable salt thereof.

7. The compound that is N-(4-(Diisobutylamino)-2′-(1H-tetrazol-5-yl)biphenyl-3-yl)-2-p-tolylacetamide or a pharmaceutically acceptable salt thereof.

8. The compound that is N,N-(4-(Benzyl(isobutyl)amino)-2′-(1H-tetrazol-5-yl)biphenyl-3-yl)-2-(2-(trifluoromethyl)phenyl)acetamide or a pharmaceutically acceptable salt thereof.

9. The compound that is 4′-(cyclohexyl(isobutyl)amino)-3′-(2-(2-fluorophenyl)acetamido)biphenyl-2-carboxylic acid or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.